Trial · NCT00664326
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Tumor Response | Regorafenib (Stivarga, BAY73-4506) | 31.3 | Percentage of participants | ||
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Complete Response (CR) | 0.0 | Percentage of participants | |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Partial Response (PR) | 31.3 | Percentage of participants | |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Stable Disease (SD) | 50.0 | Percentage of participants | |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Progressive Disease (PD) | 10.4 | Percentage of participants | |
| Tumor Response | Regorafenib (Stivarga, BAY73-4506) | Not Assessable | 8.3 | Percentage of participants | |
| Disease Control | Regorafenib (Stivarga, BAY73-4506) | 62.5 | Percentage of participants | ||
| Overall Survival | Regorafenib (Stivarga, BAY73-4506) | NA | 95% Confidence Interval 285 to NA | Days | |
| Progression-free Survival (PFS) | Regorafenib (Stivarga, BAY73-4506) | 251 | 95% Confidence Interval 160 to NA | Days | |
| Time to Progression (TTP) | Regorafenib (Stivarga, BAY73-4506) | 251 | 95% Confidence Interval 167 to NA | Days | |
| Duration of Response | Regorafenib (Stivarga, BAY73-4506) | NA | 95% Confidence Interval 140 to NA | Days | |
| Duration of Stable Disease (SD) | Regorafenib (Stivarga, BAY73-4506) | 172 | 95% Confidence Interval 107 to NA | Days | |
| Objective Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | 39.6 | Percentage of participants | ||
| Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | Complete Response (CR) | 0.0 | Percentage of participants | |
| Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | Partial Response (PR) | 39.6 | Percentage of participants | |
| Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | Stable Disease (SD) | 41.7 | Percentage of participants | |
| Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | Progressive Disease (PD) | 10.4 | Percentage of participants | |
| Tumor Response (Update) | Regorafenib (Stivarga, BAY73-4506) | Not Assessable | 8.3 | Percentage of participants | |
| Disease Control (Update) | Regorafenib (Stivarga, BAY73-4506) | 62.5 | Percentage of participants | ||
| Overall Survival (Update) | Regorafenib (Stivarga, BAY73-4506) | NA | 95% Confidence Interval 735 to NA | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00664326/results